07:00 , Sep 30, 2013 |  BC Week In Review  |  Clinical News

XTAG CYP2C19 Kit regulatory update

Luminex said FDA approved its xTAG CYP2C19 Kit for use with its MAGPIX or Luminex 100/200 instruments as an aid to clinicians in determining therapeutic strategy for therapeutics that are metabolized by the cytochrome P450...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

Verigene CYP2C19 Nucleic Acid Test regulatory update

Nanosphere said FDA granted 510(k) clearance for its Verigene CYP2C19 Nucleic Acid Test as an aid for clinicians to determine therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. The in vitro diagnostic,...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

PGXL Laboratories, SureGene LLC sales and marketing update

SureGene and partner PGXL launched the SureGene Test for Antipsychotic and Antidepressant Response (STA2R) in the U.S. The pharmacogenetic test combines the SULT4A1 genetic signature with four other tests for serotonin (5-HT) transporter ( SLC6A4...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Clopidogrel Genetic Absorption Activation Panel regulatory update

Transgenomic said it received Medicare coverage for its Clopidogrel Genetic Absorption Activation Panel as an aid to predict a patient's response to cardiovascular drug Plavix clopidogrel. The test detects deficiencies associated with genes CYP2C19 and...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

INFINITI CYP2C19 Assay regulatory update

AutoGenomics Inc. , Carlsbad, Calif.   Product: INFINITI CYP2C19 Assay ; INFINITI Warfarin Assay   Business: Diagnostic   Health Canada approved AutoGenomics' INFINITI Pharmacogenomic (PGx) testing system along with 2 related drug metabolism test kits:...
07:00 , Apr 19, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease Purinergic receptor P2Y G protein-coupled 12 (P2RY12; P2Y12) A study in rats suggests vicagrel may help prevent blood clotting in Plavix-resistant patients....
07:00 , Apr 2, 2012 |  BC Week In Review  |  Clinical News

Spartan RX CYP2C19: Phase II/III data

The open-label, Canadian Phase II/III RAPID GENE trial in 187 patients showed that Spartan's Spartan RX CYP2C19 test had 100% sensitivity and 99.3% specificity for identifying carriers of CYP2C19 mutations, which may affect the efficacy...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Clinical News

Plavix clopidogrel: Postmarketing study data

Researchers at University College London and colleagues reported data from a meta-analysis showing no significant association between cytochrome P450 2C19 (CYP2C19) genotype and cardiovascular events in patients receiving Plavix, although there was an association between...
00:38 , Dec 29, 2011 |  BC Extra  |  Clinical News

Researchers publish Plavix genotype analysis

Researchers at University College London published a meta-analysis showing no significant association between cytochrome P450 2C19 (CYP2C19) genotype and cardiovascular events in patients receiving Plavix clopidogrel. The results appear to contradict a 2010 black box...
08:00 , Nov 21, 2011 |  BC Week In Review  |  Company News

Transgenomic Inc sales and marketing update

Transgenomic also launched the FAMILION Familial Atrial Fibrillation (AF) Test in the U.S. The FAMILION genetics tests detect mutations and polymorphisms in open reading frames and intronic sequences containing splice junction sites that cause cardiac...